284 related articles for article (PubMed ID: 35323316)
1. Current Perspectives on the Importance of Pathological Features in Prognostication and Guidance of Adjuvant Chemotherapy in Colon Cancer.
Chen K; Wang H; Collins G; Hollands E; Law IYJ; Toh JWT
Curr Oncol; 2022 Feb; 29(3):1370-1389. PubMed ID: 35323316
[TBL] [Abstract][Full Text] [Related]
2. Current status on microsatellite instability, prognosis and adjuvant therapy in colon cancer: A nationwide survey of medical oncologists, colorectal surgeons and gastrointestinal pathologists.
Toh JWT; Mahajan H; Chapuis P; Spring K
Cancer Rep (Hoboken); 2021 Feb; 4(1):e1297. PubMed ID: 33030308
[TBL] [Abstract][Full Text] [Related]
3. The interaction between BRAF mutation and microsatellite instability (MSI) status in determining survival outcomes after adjuvant 5FU based chemotherapy in stage III colon cancer.
Chouhan H; Sammour T; Thomas ML; Moore JW
J Surg Oncol; 2018 Dec; 118(8):1311-1317. PubMed ID: 30399198
[TBL] [Abstract][Full Text] [Related]
4. Pathological Features and Prognostication in Colorectal Cancer.
Chen K; Collins G; Wang H; Toh JWT
Curr Oncol; 2021 Dec; 28(6):5356-5383. PubMed ID: 34940086
[TBL] [Abstract][Full Text] [Related]
5. The relationship between right-sided tumour location, tumour microenvironment, systemic inflammation, adjuvant therapy and survival in patients undergoing surgery for colon and rectal cancer.
Patel M; McSorley ST; Park JH; Roxburgh CSD; Edwards J; Horgan PG; McMillan DC
Br J Cancer; 2018 Mar; 118(5):705-712. PubMed ID: 29337962
[TBL] [Abstract][Full Text] [Related]
6. Management of stage II colon cancer - the use of molecular biomarkers for adjuvant therapy decision.
Donada M; Bonin S; Barbazza R; Pettirosso D; Stanta G
BMC Gastroenterol; 2013 Feb; 13():36. PubMed ID: 23446022
[TBL] [Abstract][Full Text] [Related]
7. [Multimodal therapy for colon cancer: state of the art].
Weber T; Link KH
Zentralbl Chir; 2011 Aug; 136(4):325-33. PubMed ID: 21863510
[TBL] [Abstract][Full Text] [Related]
8. Subgroups and prognostication in stage III colon cancer: future perspectives for adjuvant therapy.
Auclin E; Zaanan A; Vernerey D; Douard R; Gallois C; Laurent-Puig P; Bonnetain F; Taieb J
Ann Oncol; 2017 May; 28(5):958-968. PubMed ID: 28453690
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Value of BRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer.
Taieb J; Le Malicot K; Shi Q; Penault-Llorca F; Bouché O; Tabernero J; Mini E; Goldberg RM; Folprecht G; Luc Van Laethem J; Sargent DJ; Alberts SR; Emile JF; Laurent Puig P; Sinicrope FA
J Natl Cancer Inst; 2017 May; 109(5):. PubMed ID: 28040692
[TBL] [Abstract][Full Text] [Related]
10. Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial.
Ogino S; Liao X; Imamura Y; Yamauchi M; McCleary NJ; Ng K; Niedzwiecki D; Saltz LB; Mayer RJ; Whittom R; Hantel A; Benson AB; Mowat RB; Spiegelman D; Goldberg RM; Bertagnolli MM; Meyerhardt JA; Fuchs CS;
J Natl Cancer Inst; 2013 Dec; 105(23):1789-98. PubMed ID: 24231454
[TBL] [Abstract][Full Text] [Related]
11. BRAF-mutated, microsatellite-stable adenocarcinoma of the proximal colon: an aggressive adenocarcinoma with poor survival, mucinous differentiation, and adverse morphologic features.
Pai RK; Jayachandran P; Koong AC; Chang DT; Kwok S; Ma L; Arber DA; Balise RR; Tubbs RR; Shadrach B; Pai RK
Am J Surg Pathol; 2012 May; 36(5):744-52. PubMed ID: 22314188
[TBL] [Abstract][Full Text] [Related]
12. Attitudes towards Enhanced Recovery after Surgery (ERAS) interventions in colorectal surgery: nationwide survey of Australia and New Zealand colorectal surgeons.
Toh JWT; Collins GP; Pathma-Nathan N; El-Khoury T; Engel A; Smith S; Richardson A; Ctercteko G
Langenbecks Arch Surg; 2022 Jun; 407(4):1637-1646. PubMed ID: 35275247
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant chemotherapy in stage II and III colon cancer: the role of the "budding and TILs-(tumor-infiltrating lymphocytes) combination" as tumor-host antagonists.
Lang-Schwarz C; Melcher B; Dregelies T; Norouzzadeh Z; Rund-Küffner S; Lang-Schwarz K; Vieth M; Sterlacci W
Int J Colorectal Dis; 2021 Aug; 36(8):1765-1779. PubMed ID: 33745027
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study.
André T; de Gramont A; Vernerey D; Chibaudel B; Bonnetain F; Tijeras-Raballand A; Scriva A; Hickish T; Tabernero J; Van Laethem JL; Banzi M; Maartense E; Shmueli E; Carlsson GU; Scheithauer W; Papamichael D; Möehler M; Landolfi S; Demetter P; Colote S; Tournigand C; Louvet C; Duval A; Fléjou JF; de Gramont A
J Clin Oncol; 2015 Dec; 33(35):4176-87. PubMed ID: 26527776
[TBL] [Abstract][Full Text] [Related]
15. Retrospective analysis of a Bi-National Colorectal Cancer Audit to characterize stage II colon cancer patients who were offered adjuvant chemotherapy.
Cooper EA; Buxey KN; Maslen BJ; Muhlmann M
ANZ J Surg; 2020 Jun; 90(6):1136-1140. PubMed ID: 32072761
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of BRAF mutation alone and in combination with microsatellite instability in stage III colon cancer.
Chouhan H; Sammour T; L Thomas M; W Moore J
Asia Pac J Clin Oncol; 2019 Feb; 15(1):69-74. PubMed ID: 30421554
[TBL] [Abstract][Full Text] [Related]
17. The prognostic impact of primary tumour location in patients with stage II and stage III colon cancer receiving adjuvant therapy. A GISCAD analysis from three large randomised trials.
Cascinu S; Poli D; Zaniboni A; Lonardi S; Labianca R; Sobrero A; Rosati G; Di Bartolomeo M; Scartozzi M; Zagonel V; Pella N; Banzi M; Torri V
Eur J Cancer; 2019 Apr; 111():1-7. PubMed ID: 30797014
[TBL] [Abstract][Full Text] [Related]
18. Relationship Between Metformin Use and Recurrence and Survival in Patients With Resected Stage III Colon Cancer Receiving Adjuvant Chemotherapy: Results From North Central Cancer Treatment Group N0147 (Alliance).
Singh PP; Shi Q; Foster NR; Grothey A; Nair SG; Chan E; Shields AF; Goldberg RM; Gill S; Kahlenberg MS; Sinicrope FA; Sargent DJ; Alberts SR
Oncologist; 2016 Dec; 21(12):1509-1521. PubMed ID: 27881709
[TBL] [Abstract][Full Text] [Related]
19. Predictors of lymph node count in colorectal cancer resections: data from US nationwide prospective cohort studies.
Morikawa T; Tanaka N; Kuchiba A; Nosho K; Yamauchi M; Hornick JL; Swanson RS; Chan AT; Meyerhardt JA; Huttenhower C; Schrag D; Fuchs CS; Ogino S
Arch Surg; 2012 Aug; 147(8):715-23. PubMed ID: 22508672
[TBL] [Abstract][Full Text] [Related]
20. Recent approaches to identifying biomarkers for high-risk stage II colon cancer.
Akiyoshi T; Kobunai T; Watanabe T
Surg Today; 2012 Nov; 42(11):1037-45. PubMed ID: 22961195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
